Sofia, Bulgaria, January 27, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD notifies that in compliance with the decision of the Board of Directors of "Sopharma" AD dated 26.10.2022, the Company submitted for approval to the Financial Supervision Commission an Agreement for conversion by merger of the subsidiary company "Biopharm-engineering" AD, UIC: 119055339 in "Sopharma” AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on Public Offering of Securities.

Sofia, Bulgaria, January 20, 2023 - Pursuant to the requirements of Art. 154, para.

Sofia, Bulgaria, January 13, 2023 – According to the requirements of art. 100t of LPOS, the Board of Directors of "Sopharma" AD announces that on January 13, 2023, "Sopharma" AD received a corrected tender offer, registered with the Financial Supervision Commission from "DONEV INVESTMENTS HOLDING" AD - a shareholder directly owning 37,600,000 ordinary, non-available shares with voting rights, representing 27.89% of the capital and votes in the GMS of "SOPHARMA" AD, on the basis of art.

Sofia, Bulgaria, January 11, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD notifies that for December 2022 the Company recorded an increase in sales of 19% compared to the same month of the previous year, incl. 14% increase in domestic sales and 21% increase in export sales.

For 2022 the revenues from sales of products increase by 15%, incl. 10% increase of sales for the domestic market and 19% increase in export sales.